3 Key Takeaways
Plain English Summary- 01Core Finding
Liver biopsy, the historical reference standard, is invasive, subject to sampling error and not scalable.
- 02Study Evidence
Tested in a observational cohort study at the real-world cohort stage.
- 03Practical Meaning
Artificial intelligence may broaden access by automating analysis and enabling PDFF from routine MRI.
What This Means for You
Composite scores, MAST, MEFIB, and MASH Resolution Index, combine imaging and blood tests for advanced fibrosis (tissue scarring) diagnosis and response assessment. MRE is cost-effective compared with vibration-controlled transient elastography for detecting advanced fibrosis. Artificial intelligence may broaden access by automating analysis and enabling PDFF from routine MRI. We review the evidence supporting these biomarkers for diagnosis, prognosis and regulatory use, and their role in clinical trials and in treatment decisions for approved MASH therapies.
The Discovery
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects up to 38% of the population globally. Liver biopsy, the historical reference standard, is invasive, subject to sampling error and not scalable. MRI-based biomarkers provide non-invasive, quantitative whole liver assessment. MRI proton density fat fraction (MRI-PDFF) is the most accurate noninvasive measure of steatosis (thresholds of 6.4%, 17.4% and 22.1% for grades ≥1, ≥2 and 3), and a ≥a clinically meaningful level relative reduction is associated with histologic response. Liver stiffness by magnetic resonance elastography (MRE-LS) is the most accurate imaging biomarker (measurable biological signal) for fibrosis (tissue scarring): MRE-LS of 3.1-4.4 kPa corresponds to F2-F3 and ≥5 kPa to cirrhosis, and each 1-kPa increase is associated with a 43% higher risk of hepatic decompensation. Iron-corrected T1 is a sensitive but nonspecific marker of disease activity whose prognostic value requires further study.
How It Works, Simply
This gastroenterology research focuses on blood biomarker (measurable biological signal). Researchers evaluated it using an observational cohort study at the real-world cohort stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
Liver biopsy, the historical reference standard, is invasive, subject to sampling error and not scalable.
- 02Study Evidence
Tested in a observational cohort study at the real-world cohort stage.
- 03Practical Meaning
Artificial intelligence may broaden access by automating analysis and enabling PDFF from routine MRI.
Key Numbers
Biological Mechanism & Study Design
Study Design & Cohort
Observational cohort study
Observational cohort study · Real-World Cohort
Biological Pathway & Modality
Blood biomarker
Intervention: MRI-based biomarkers for risk stratification and assessment of treatment response in
Experimental Findings & Endpoints
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects up to 38% of the population globally.
Liver biopsy, the historical reference standard, is invasive, subject to sampling error and not scalable. MRI-based biomarkers provide non-invasive, quantitative whole liver assessment.
MRI proton density fat fraction (MRI-PDFF) is the most accurate noninvasive measure of steatosis (thresholds of 6.4%, 17.4% and 22.1% for grades ≥1, ≥2 and 3), and a ≥a clinically meaningful level relative reduction is associated with histologic response. Liver stiffness by magnetic resonance elastography (MRE-LS) is the most accurate imaging biomarker for fibrosis: MRE-LS of 3.1-4.4 kPa corresponds to F2-F3 and ≥5 kPa to cirrhosis, and each 1-kPa increase is associated with a 43% higher risk of hepatic decompensation.
Iron-corrected T1 is a sensitive but nonspecific marker of disease activity whose prognostic value requires further study.
Clinical Translation & Practice Context
Composite scores, MAST, MEFIB, and MASH Resolution Index, combine imaging and blood tests for advanced fibrosis diagnosis and response assessment.
MRE is cost-effective compared with vibration-controlled transient elastography for detecting advanced fibrosis. Artificial intelligence may broaden access by automating analysis and enabling PDFF from routine MRI.
We review the evidence supporting these biomarkers for diagnosis, prognosis and regulatory use, and their role in clinical trials and in treatment decisions for approved MASH therapies.
The Bottom Line · Clinical Pearl
“We review the evidence supporting these biomarkers for diagnosis, prognosis and regulatory use, and their role in clinical trials and in treatment decisions for approved MASH therapies.”
Published in Hepatology (baltimore, Md.) · Current Stage: Real-World Cohort
